Summary

CRISPR-based Gene Editing Market Summary
The global CRISPR-based gene editing market size was estimated at USD 4.01 billion in 2024 and is projected to reach USD 13.50 billion by 2033, growing at a CAGR of 14.7% from 2025 to 2033. This growth is driven by the rising prevalence of genetic disorders, advancements in research and technology, supportive government initiatives, and increasing investment in biotechnology.

Advancements in CRISPR Technology & Applications

Advancements in CRISPR technology and applications are significantly accelerating market growth by enhancing precision, efficiency, and versatility in gene editing. Since its discovery, the CRISPR-Cas system has evolved beyond basic DNA cutting into a sophisticated genome engineering platform. It is supported by innovations such as high-fidelity Cas variants, base editing, prime editing, and improved delivery mechanisms such as lipid nanoparticles and viral vectors. These improvements have reduced off-target effects, increased editing efficiency, and broadened the scope of treatable conditions. Integration with artificial intelligence (AI) and machine learning has further optimized guide RNA design and target site selection, enabling faster, more accurate development cycles. Technology’s adaptability also supports multiplexed editing, allowing simultaneous modification of multiple genes crucial for tackling complex diseases and traits.

These advancements also expand CRISPR into new application areas beyond human therapeutics, including agriculture, industrial biotechnology, diagnostics, and environmental management. In agriculture, CRISPR is being applied to create climate-resilient, pest-resistant, and nutrient-enhanced crops, offering solutions to food security challenges. In diagnostics, CRISPR-based tools such as SHERLOCK and FELUDA enable rapid, low-cost detection of infectious diseases. At the same time, in synthetic biology, CRISPR is used to engineer microorganisms for sustainable biofuel and material production. The widening scope of CRISPR applications, coupled with ongoing technical refinements, is attracting strong investments from pharmaceutical companies, agri-biotech firms, and research institutions. This continual innovation cycle expands the addressable market and strengthens CRISPR’s position as a transformative technology platform across multiple industries.

Global CRISPR-based Gene Editing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CRISPR-based gene editing market based on product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Products
o CRISPR Kits & Reagents
o CRISPR Libraries
o Others
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Biomedical
o Therapeutic Development
o By Indication
o Genetic Disorders
o Oncology
o Ophthalmology
o Others
o By Delivery Method
o Ex Vivo
o In Vivo
o Disease Diagnostics
• Agricultural applications
o Plant Engineering
o Farm Animals Engineering
o Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• MEA
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product & Service Segment
1.2.2. Application Segment
1.2.3. End Use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. CRISPR-based Gene Editing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of genetic disorders
3.2.1.2. Growing investments in biotechnology and healthcare research
3.2.1.3. Advancements in CRISPR technology and applications
3.2.2. Market restraint analysis
3.2.2.1. Ethical concerns surrounding gene editing
3.2.2.2. High costs associated with CRISPR research and development
3.3. CRISPR-based Gene Editing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. CRISPR-based Gene Editing Market: Product & Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global CRISPR-based Gene Editing Market Product & Service Movement Analysis
4.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
4.4. Products
4.4.1. Products market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. CRISPR Kits & Reagents
4.4.2.1. CRISPR kits & reagents market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. CRISPR Libraries
4.4.3.1. CRISPR libraries market estimates and forecasts 2021 to 2033 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. CRISPR-based Gene Editing Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global CRISPR-based Gene Editing Market Application Movement Analysis
5.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Biomedical
5.4.1. Biomedical market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Therapeutic Development
5.4.2.1. Therapeutic development market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.2. By Indication
5.4.2.2.1. Genetic Disorders
5.4.2.2.1.1. Genetic Disorders market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.2.2. Oncology
5.4.2.2.2.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.2.3. Ophthalmology
5.4.2.2.3.1. Ophthalmology market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.2.4. Others
5.4.2.2.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.3. By Delivery Method
5.4.2.3.1. Ex Vivo
5.4.2.3.1.1. Ex vivo market estimates and forecasts 2021 to 2033 (USD Million
5.4.2.3.2. In Vivo
5.4.2.3.2.1. In vivo market estimates and forecasts 2021 to 2033 (USD Million
5.4.3. Disease Diagnostics
5.4.3.1. Disease diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Agricultural applications
5.5.1. Agricultural applications market estimates and forecasts 2021 to 2033 (USD Million)
5.5.2. Plant Engineering
5.5.2.1. Plant engineering market estimates and forecasts 2021 to 2033 (USD Million)
5.5.3. Farm Animals Engineering
5.5.3.1. Farm animals engineering market estimates and forecasts 2021 to 2033 (USD Million)
5.5.4. Others
5.5.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. CRISPR-based Gene Editing Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global CRISPR-based Gene Editing Market End Use Movement Analysis
6.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Contract Research Organizations
6.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. CRISPR-based Gene Editing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Target disease prevalence
7.4.2.4. Regulatory framework
7.4.2.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Target disease prevalence
7.4.3.4. Regulatory framework
7.4.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Target disease prevalence
7.4.4.4. Regulatory framework
7.4.4.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Europe
7.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Target disease prevalence
7.5.2.4. Regulatory framework
7.5.2.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Target disease prevalence
7.5.3.4. Regulatory framework
7.5.3.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Target disease prevalence
7.5.4.4. Regulatory framework
7.5.4.5. France market estimates and forecasts 2021 to 2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Target disease prevalence
7.5.5.4. Regulatory framework
7.5.5.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Target disease prevalence
7.5.6.4. Regulatory framework
7.5.6.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Target disease prevalence
7.5.7.4. Regulatory framework
7.5.7.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key country dynamics
7.5.8.2. Competitive scenario
7.5.8.3. Target disease prevalence
7.5.8.4. Regulatory framework
7.5.8.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key country dynamics
7.5.9.2. Competitive scenario
7.5.9.3. Target disease prevalence
7.5.9.4. Regulatory framework
7.5.9.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Target disease prevalence
7.6.2.4. Regulatory framework
7.6.2.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. China
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Target disease prevalence
7.6.3.4. Regulatory framework
7.6.3.5. China market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Competitive scenario
7.6.4.3. Target disease prevalence
7.6.4.4. Regulatory framework
7.6.4.5. India market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key country dynamics
7.6.5.2. Competitive scenario
7.6.5.3. Target disease prevalence
7.6.5.4. Regulatory framework
7.6.5.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key country dynamics
7.6.6.2. Competitive scenario
7.6.6.3. Target disease prevalence
7.6.6.4. Regulatory framework
7.6.6.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Competitive scenario
7.6.7.3. Target disease prevalence
7.6.7.4. Regulatory framework
7.6.7.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Latin America
7.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Target disease prevalence
7.7.2.4. Regulatory framework
7.7.2.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Target disease prevalence
7.7.3.4. Regulatory framework
7.7.3.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.8. MEA
7.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Competitive scenario
7.8.2.3. Target disease prevalence
7.8.2.4. Regulatory framework
7.8.2.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Competitive scenario
7.8.3.3. Target disease prevalence
7.8.3.4. Regulatory framework
7.8.3.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Competitive scenario
7.8.4.3. Target disease prevalence
7.8.4.4. Regulatory framework
7.8.4.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Competitive scenario
7.8.5.3. Target disease prevalence
7.8.5.4. Regulatory framework
7.8.5.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Company Profiles/Listing
8.4.1. Revvity, Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product/Service benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Danaher Corporation
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/Service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. GenScript
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/Service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Merck KGaA
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/Service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Thermo Fisher Scientific, Inc.
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/Service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Tocris Bioscience
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/Service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. OriGene Technologies, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/Service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Bio-Rad Laboratories
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/Service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Bio-Techne
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/Service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. New England Biolabs, Inc.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/Service benchmarking
8.4.10.4. Strategic initiatives